SK11162002A3 - Kondenzované azolové zlúčeniny a ich použitie ako hypoglykemické prostriedky - Google Patents

Kondenzované azolové zlúčeniny a ich použitie ako hypoglykemické prostriedky Download PDF

Info

Publication number: SK11162002A3
Authority: SK; Slovakia
Prior art keywords: oxo; ethoxy; formula; benzyl; benzothiazol
Prior art date: 2000-02-02

Application number

SK1116-2002A

Other languages

English (en)

Slovak (sk)

Inventor

Daniel Lesieur

Elodie Blanc-Delmas

Said Yous

Patrick Depreux

G�Rald Guillaumet

Catherine Dacquet

Nigel Levens

Jean Albert Boutin

Caroline Bennejean

Pierre Renard

Original Assignee

Les Laboratoires Servier

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-02-02

Filing date

2001-02-01

Publication date

2003-01-09

2001-02-01 Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier

2003-01-09 Publication of SK11162002A3 publication Critical patent/SK11162002A3/sk

Links

239000003472 antidiabetic agent Substances 0.000 title description 3
150000003851 azoles Chemical class 0.000 title description 2
229940126904 hypoglycaemic agent Drugs 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 173
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 18
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims abstract description 16
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 9
229910052760 oxygen Inorganic materials 0.000 claims abstract description 9
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims abstract description 8
239000001301 oxygen Substances 0.000 claims abstract description 8
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims abstract description 6
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 5
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims abstract description 4
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims abstract description 4
125000002947 alkylene group Chemical group 0.000 claims abstract description 4
PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims abstract 2
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 102
238000000034 method Methods 0.000 claims description 84
-1 hydroxy, amino Chemical group 0.000 claims description 71
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 65
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 62
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 37
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 34
239000002253 acid Substances 0.000 claims description 28
150000003839 salts Chemical class 0.000 claims description 27
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 26
125000000217 alkyl group Chemical group 0.000 claims description 25
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 17
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 16
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims description 16
125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 16
238000011282 treatment Methods 0.000 claims description 15
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 14
125000003118 aryl group Chemical group 0.000 claims description 12
229910052717 sulfur Inorganic materials 0.000 claims description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
229910052739 hydrogen Inorganic materials 0.000 claims description 11
239000001257 hydrogen Substances 0.000 claims description 11
125000001424 substituent group Chemical group 0.000 claims description 10
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 9
125000005843 halogen group Chemical group 0.000 claims description 9
238000002360 preparation method Methods 0.000 claims description 9
208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 8
125000003342 alkenyl group Chemical group 0.000 claims description 8
206010012601 diabetes mellitus Diseases 0.000 claims description 8
125000001072 heteroaryl group Chemical group 0.000 claims description 8
125000005842 heteroatom Chemical group 0.000 claims description 8
239000011593 sulfur Chemical group 0.000 claims description 8
102000004877 Insulin Human genes 0.000 claims description 7
108090001061 Insulin Proteins 0.000 claims description 7
206010022489 Insulin Resistance Diseases 0.000 claims description 7
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
229940125396 insulin Drugs 0.000 claims description 7
208000008589 Obesity Diseases 0.000 claims description 6
125000000304 alkynyl group Chemical group 0.000 claims description 6
201000001421 hyperglycemia Diseases 0.000 claims description 6
125000000896 monocarboxylic acid group Chemical group 0.000 claims description 6
235000020824 obesity Nutrition 0.000 claims description 6
229910052763 palladium Inorganic materials 0.000 claims description 6
229910052757 nitrogen Chemical group 0.000 claims description 5
230000008569 process Effects 0.000 claims description 5
125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 claims description 4
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
208000024172 Cardiovascular disease Diseases 0.000 claims description 4
108090000790 Enzymes Proteins 0.000 claims description 4
102000004190 Enzymes Human genes 0.000 claims description 4
206010028980 Neoplasm Diseases 0.000 claims description 4
150000001555 benzenes Chemical class 0.000 claims description 4
125000004432 carbon atom Chemical group C* 0.000 claims description 4
238000009833 condensation Methods 0.000 claims description 4
230000005494 condensation Effects 0.000 claims description 4
125000004093 cyano group Chemical group *C#N 0.000 claims description 4
230000001419 dependent effect Effects 0.000 claims description 4
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 4
208000035475 disorder Diseases 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
125000004043 oxo group Chemical group O=* 0.000 claims description 4
239000000825 pharmaceutical preparation Substances 0.000 claims description 4
238000011321 prophylaxis Methods 0.000 claims description 4
238000000926 separation method Methods 0.000 claims description 4
GXGJIOMUZAGVEH-UHFFFAOYSA-N Chamazulene Chemical group CCC1=CC=C(C)C2=CC=C(C)C2=C1 GXGJIOMUZAGVEH-UHFFFAOYSA-N 0.000 claims description 3
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 3
208000032928 Dyslipidaemia Diseases 0.000 claims description 3
208000002705 Glucose Intolerance Diseases 0.000 claims description 3
206010018429 Glucose tolerance impaired Diseases 0.000 claims description 3
208000017170 Lipid metabolism disease Diseases 0.000 claims description 3
208000001132 Osteoporosis Diseases 0.000 claims description 3
201000004681 Psoriasis Diseases 0.000 claims description 3
125000003545 alkoxy group Chemical group 0.000 claims description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
XZPPSQZLRAAUJC-UHFFFAOYSA-N diethyl 2-[[4-[2-(2-oxo-1,3-benzoxazol-3-yl)ethoxy]phenyl]methylidene]propanedioate Chemical compound C1=CC(C=C(C(=O)OCC)C(=O)OCC)=CC=C1OCCN1C(=O)OC2=CC=CC=C21 XZPPSQZLRAAUJC-UHFFFAOYSA-N 0.000 claims description 3
SAZTWDWOVBGDEY-UHFFFAOYSA-N dimethyl 2-[[4-[2-[6-(3-chlorobenzoyl)-2-oxo-1,3-benzothiazol-3-yl]ethoxy]phenyl]methyl]propanedioate Chemical compound C1=CC(CC(C(=O)OC)C(=O)OC)=CC=C1OCCN1C(=O)SC2=CC(C(=O)C=3C=C(Cl)C=CC=3)=CC=C21 SAZTWDWOVBGDEY-UHFFFAOYSA-N 0.000 claims description 3
229910052736 halogen Inorganic materials 0.000 claims description 3
150000002367 halogens Chemical class 0.000 claims description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
125000004957 naphthylene group Chemical group 0.000 claims description 3
230000007170 pathology Effects 0.000 claims description 3
125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 3
125000004434 sulfur atom Chemical group 0.000 claims description 3
208000011580 syndromic disease Diseases 0.000 claims description 3
125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 2
125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 2
125000006729 (C2-C5) alkenyl group Chemical group 0.000 claims description 2
125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims description 2
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims description 2
NCGMEYVRNOTGME-UHFFFAOYSA-N 2-[[4-[2-(2-oxo-1,3-benzothiazol-3-yl)ethoxy]phenyl]methyl]propanedioic acid Chemical compound C1=CC(CC(C(=O)O)C(O)=O)=CC=C1OCCN1C(=O)SC2=CC=CC=C21 NCGMEYVRNOTGME-UHFFFAOYSA-N 0.000 claims description 2
JRYDZRHSOBWDJZ-UHFFFAOYSA-N 2-[[4-[2-(6-benzoyl-2-oxo-1,3-benzothiazol-3-yl)ethoxy]phenyl]methyl]propanedioic acid Chemical compound C1=CC(CC(C(=O)O)C(O)=O)=CC=C1OCCN1C(=O)SC2=CC(C(=O)C=3C=CC=CC=3)=CC=C21 JRYDZRHSOBWDJZ-UHFFFAOYSA-N 0.000 claims description 2
125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 2
VEMYIMWMTBPTMV-UHFFFAOYSA-N 3-ethoxy-3-oxo-2-[[4-[2-(2-oxo-1,3-benzothiazol-3-yl)ethoxy]phenyl]methyl]propanoic acid Chemical compound C1=CC(CC(C(=O)OCC)C(O)=O)=CC=C1OCCN1C(=O)SC2=CC=CC=C21 VEMYIMWMTBPTMV-UHFFFAOYSA-N 0.000 claims description 2
XOMUEKJGHKBIRW-UHFFFAOYSA-N 3-ethoxy-3-oxo-2-[[4-[2-(2-oxo-1,3-benzoxazol-3-yl)ethoxy]phenyl]methyl]propanoic acid Chemical compound C1=CC(CC(C(=O)OCC)C(O)=O)=CC=C1OCCN1C(=O)OC2=CC=CC=C21 XOMUEKJGHKBIRW-UHFFFAOYSA-N 0.000 claims description 2
125000001999 4-Methoxybenzoyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C(*)=O 0.000 claims description 2
208000000103 Anorexia Nervosa Diseases 0.000 claims description 2
200000000007 Arterial disease Diseases 0.000 claims description 2
206010003210 Arteriosclerosis Diseases 0.000 claims description 2
206010006187 Breast cancer Diseases 0.000 claims description 2
208000026310 Breast neoplasm Diseases 0.000 claims description 2
206010006550 Bulimia nervosa Diseases 0.000 claims description 2
125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 2
206010009944 Colon cancer Diseases 0.000 claims description 2
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 2
238000006546 Horner-Wadsworth-Emmons reaction Methods 0.000 claims description 2
206010068871 Myotonic dystrophy Diseases 0.000 claims description 2
206010033645 Pancreatitis Diseases 0.000 claims description 2
206010048214 Xanthoma Diseases 0.000 claims description 2
206010048215 Xanthomatosis Diseases 0.000 claims description 2
125000003368 amide group Chemical group 0.000 claims description 2
208000022531 anorexia Diseases 0.000 claims description 2
208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
125000004104 aryloxy group Chemical group 0.000 claims description 2
235000010290 biphenyl Nutrition 0.000 claims description 2
239000004305 biphenyl Substances 0.000 claims description 2
210000000481 breast Anatomy 0.000 claims description 2
201000011510 cancer Diseases 0.000 claims description 2
239000003054 catalyst Substances 0.000 claims description 2
238000009903 catalytic hydrogenation reaction Methods 0.000 claims description 2
239000003638 chemical reducing agent Substances 0.000 claims description 2
208000029742 colonic neoplasm Diseases 0.000 claims description 2
238000006114 decarboxylation reaction Methods 0.000 claims description 2
206010061428 decreased appetite Diseases 0.000 claims description 2
125000004663 dialkyl amino group Chemical group 0.000 claims description 2
ACUXLXXHQFVCQC-UHFFFAOYSA-N diethyl 2-[[4-[2-(2-oxo-1,3-benzoxazol-3-yl)ethoxy]phenyl]methyl]propanedioate Chemical compound C1=CC(CC(C(=O)OCC)C(=O)OCC)=CC=C1OCCN1C(=O)OC2=CC=CC=C21 ACUXLXXHQFVCQC-UHFFFAOYSA-N 0.000 claims description 2
NSMJEHGOMXSLCW-UHFFFAOYSA-N dimethyl 2-[[4-[2-(6-benzoyl-2-oxo-1,3-benzothiazol-3-yl)ethoxy]phenyl]methyl]propanedioate Chemical compound C1=CC(CC(C(=O)OC)C(=O)OC)=CC=C1OCCN1C(=O)SC2=CC(C(=O)C=3C=CC=CC=3)=CC=C21 NSMJEHGOMXSLCW-UHFFFAOYSA-N 0.000 claims description 2
LWUHDBCYJQNIDR-UHFFFAOYSA-N dimethyl 2-[[4-[2-(6-benzoyl-2-oxo-1,3-benzoxazol-3-yl)ethoxy]phenyl]methyl]propanedioate Chemical compound C1=CC(CC(C(=O)OC)C(=O)OC)=CC=C1OCCN1C(=O)OC2=CC(C(=O)C=3C=CC=CC=3)=CC=C21 LWUHDBCYJQNIDR-UHFFFAOYSA-N 0.000 claims description 2
125000004185 ester group Chemical group 0.000 claims description 2
150000002148 esters Chemical class 0.000 claims description 2
230000037406 food intake Effects 0.000 claims description 2
235000012631 food intake Nutrition 0.000 claims description 2
229940088597 hormone Drugs 0.000 claims description 2
239000005556 hormone Substances 0.000 claims description 2
208000017169 kidney disease Diseases 0.000 claims description 2
125000001624 naphthyl group Chemical group 0.000 claims description 2
125000004430 oxygen atom Chemical group O* 0.000 claims description 2
230000002265 prevention Effects 0.000 claims description 2
150000004892 pyridazines Chemical class 0.000 claims description 2
239000007858 starting material Substances 0.000 claims description 2
150000003606 tin compounds Chemical class 0.000 claims description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
125000006685 (C1-C6) polyhaloalkyl group Chemical group 0.000 claims 1
125000001088 1-naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 claims 1
BDFRZZJKMDFESX-UHFFFAOYSA-N 2-[[4-[2-(6-benzoyl-2-oxo-1,3-benzothiazol-3-yl)ethoxy]phenyl]methyl]-3-methoxy-3-oxopropanoic acid Chemical compound C1=CC(CC(C(=O)OC)C(O)=O)=CC=C1OCCN1C(=O)SC2=CC(C(=O)C=3C=CC=CC=3)=CC=C21 BDFRZZJKMDFESX-UHFFFAOYSA-N 0.000 claims 1
125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 claims 1
125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims 1
208000032841 Bulimia Diseases 0.000 claims 1
208000017442 Retinal disease Diseases 0.000 claims 1
206010038923 Retinopathy Diseases 0.000 claims 1
239000004480 active ingredient Substances 0.000 claims 1
239000004037 angiogenesis inhibitor Substances 0.000 claims 1
229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
125000005129 aryl carbonyl group Chemical group 0.000 claims 1
230000020411 cell activation Effects 0.000 claims 1
239000000539 dimer Substances 0.000 claims 1
DGTTVPRXEKLDPR-UHFFFAOYSA-N dimethyl 2-[[4-(2-pyrrolo[2,3-b]pyridin-1-ylethoxy)phenyl]methyl]propanedioate Chemical compound C1=CC(CC(C(=O)OC)C(=O)OC)=CC=C1OCCN1C2=NC=CC=C2C=C1 DGTTVPRXEKLDPR-UHFFFAOYSA-N 0.000 claims 1
210000002889 endothelial cell Anatomy 0.000 claims 1
125000001841 imino group Chemical group [H]N=* 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
125000006413 ring segment Chemical group 0.000 claims 1
125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 90
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 63
230000008018 melting Effects 0.000 description 58
238000002844 melting Methods 0.000 description 58
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 54
239000000203 mixture Substances 0.000 description 53
239000000543 intermediate Substances 0.000 description 35
HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 27
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
239000002904 solvent Substances 0.000 description 23
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
239000002244 precipitate Substances 0.000 description 21
239000011541 reaction mixture Substances 0.000 description 21
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 20
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 19
238000001704 evaporation Methods 0.000 description 18
230000008020 evaporation Effects 0.000 description 18
239000000047 product Substances 0.000 description 17
238000001953 recrystallisation Methods 0.000 description 17
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
239000012074 organic phase Substances 0.000 description 13
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
IKCLCGXPQILATA-UHFFFAOYSA-N 2-chlorobenzoic acid Chemical group OC(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-N 0.000 description 11
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 11
229910052943 magnesium sulfate Inorganic materials 0.000 description 10
235000019341 magnesium sulphate Nutrition 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 9
230000000694 effects Effects 0.000 description 9
LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 8
ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 8
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 8
239000008346 aqueous phase Substances 0.000 description 8
238000001914 filtration Methods 0.000 description 8
238000010992 reflux Methods 0.000 description 8
208000031226 Hyperlipidaemia Diseases 0.000 description 7
239000012298 atmosphere Substances 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
201000010099 disease Diseases 0.000 description 7
239000012071 phase Substances 0.000 description 7
230000003178 anti-diabetic effect Effects 0.000 description 6
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
BEPAFCGSDWSTEL-UHFFFAOYSA-N dimethyl malonate Chemical compound COC(=O)CC(=O)OC BEPAFCGSDWSTEL-UHFFFAOYSA-N 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
235000019260 propionic acid Nutrition 0.000 description 6
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
239000008280 blood Substances 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
238000000354 decomposition reaction Methods 0.000 description 5
IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 5
238000003818 flash chromatography Methods 0.000 description 5
239000008103 glucose Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
BXQNSPXDWSNUKE-UHFFFAOYSA-N 1,3-benzothiazole 1-oxide Chemical compound C1=CC=C2S(=O)C=NC2=C1 BXQNSPXDWSNUKE-UHFFFAOYSA-N 0.000 description 4
IBYHHJPAARCAIE-UHFFFAOYSA-N 1-bromo-2-chloroethane Chemical compound ClCCBr IBYHHJPAARCAIE-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
238000010171 animal model Methods 0.000 description 4
HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 4
DMFAVCDAGDIDPH-UHFFFAOYSA-N dimethyl 2-[[4-(2-chloroethoxy)phenyl]methylidene]propanedioate Chemical compound COC(=O)C(C(=O)OC)=CC1=CC=C(OCCCl)C=C1 DMFAVCDAGDIDPH-UHFFFAOYSA-N 0.000 description 4
230000000055 hyoplipidemic effect Effects 0.000 description 4
DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 4
230000002093 peripheral effect Effects 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
238000000746 purification Methods 0.000 description 4
229960004586 rosiglitazone Drugs 0.000 description 4
239000000741 silica gel Substances 0.000 description 4
229910002027 silica gel Inorganic materials 0.000 description 4
239000007787 solid Substances 0.000 description 4
AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 4
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical group O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 3
WWYDYZMNFQIYPT-UHFFFAOYSA-L 2-phenylpropanedioate Chemical compound [O-]C(=O)C(C([O-])=O)C1=CC=CC=C1 WWYDYZMNFQIYPT-UHFFFAOYSA-L 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
239000005711 Benzoic acid Substances 0.000 description 3
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
229940123464 Thiazolidinedione Drugs 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
210000000577 adipose tissue Anatomy 0.000 description 3
235000010233 benzoic acid Nutrition 0.000 description 3
230000037396 body weight Effects 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
239000003208 petroleum Substances 0.000 description 3
229910000027 potassium carbonate Inorganic materials 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
JIABGVRRDCSMKD-UHFFFAOYSA-N 2-[[4-(2-pyrrolo[2,3-b]pyridin-1-ylethoxy)phenyl]methyl]propanedioic acid Chemical compound C1=CC(CC(C(=O)O)C(O)=O)=CC=C1OCCN1C2=NC=CC=C2C=C1 JIABGVRRDCSMKD-UHFFFAOYSA-N 0.000 description 2
CEIJNATZYZJREB-UHFFFAOYSA-N 2-[[4-[2-(2-oxo-1,3-benzoxazol-3-yl)ethoxy]phenyl]methyl]propanedioic acid Chemical compound C1=CC(CC(C(=O)O)C(O)=O)=CC=C1OCCN1C(=O)OC2=CC=CC=C21 CEIJNATZYZJREB-UHFFFAOYSA-N 0.000 description 2
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 2
BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 2
LULAYUGMBFYYEX-UHFFFAOYSA-N 3-chlorobenzoic acid Chemical group OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 2
ARMODHYRVSVWPI-UHFFFAOYSA-N 3-methoxy-3-oxo-2-[[4-[2-(2-oxo-1,3-benzothiazol-3-yl)ethoxy]phenyl]methyl]propanoic acid Chemical compound C1=CC(CC(C(=O)OC)C(O)=O)=CC=C1OCCN1C(=O)SC2=CC=CC=C21 ARMODHYRVSVWPI-UHFFFAOYSA-N 0.000 description 2
OAKURXIZZOAYBC-UHFFFAOYSA-N 3-oxopropanoic acid Chemical compound OC(=O)CC=O OAKURXIZZOAYBC-UHFFFAOYSA-N 0.000 description 2
KJEZFSSXQNYARA-UHFFFAOYSA-N 4-[2-(2-oxo-1,3-benzoxazol-3-yl)ethoxy]benzaldehyde Chemical compound C1=CC(C=O)=CC=C1OCCN1C(=O)OC2=CC=CC=C21 KJEZFSSXQNYARA-UHFFFAOYSA-N 0.000 description 2
RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 2
ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical group COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 2
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical group CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
206010012289 Dementia Diseases 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
206010019280 Heart failures Diseases 0.000 description 2
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical group Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
208000035150 Hypercholesterolemia Diseases 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
229960000583 acetic acid Drugs 0.000 description 2
125000000676 alkoxyimino group Chemical group 0.000 description 2
208000037849 arterial hypertension Diseases 0.000 description 2
238000010533 azeotropic distillation Methods 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
238000011161 development Methods 0.000 description 2
UKTBBMUEIHEGHI-UHFFFAOYSA-N dimethyl 2-[[4-[2-[6-(2-chlorobenzoyl)-2-oxo-1,3-benzothiazol-3-yl]ethoxy]phenyl]methyl]propanedioate Chemical compound C1=CC(CC(C(=O)OC)C(=O)OC)=CC=C1OCCN1C(=O)SC2=CC(C(=O)C=3C(=CC=CC=3)Cl)=CC=C21 UKTBBMUEIHEGHI-UHFFFAOYSA-N 0.000 description 2
DXMDVEQLGCZRIL-UHFFFAOYSA-N dimethyl 2-[[4-[2-[6-(2-chlorobenzoyl)-2-oxo-1,3-benzothiazol-3-yl]ethoxy]phenyl]methylidene]propanedioate Chemical compound C1=CC(C=C(C(=O)OC)C(=O)OC)=CC=C1OCCN1C(=O)SC2=CC(C(=O)C=3C(=CC=CC=3)Cl)=CC=C21 DXMDVEQLGCZRIL-UHFFFAOYSA-N 0.000 description 2
ASZASBBFPCQNFC-UHFFFAOYSA-N dimethyl 2-[[4-[2-[6-(naphthalene-1-carbonyl)-2-oxo-1,3-benzothiazol-3-yl]ethoxy]phenyl]methyl]propanedioate Chemical compound C1=CC(CC(C(=O)OC)C(=O)OC)=CC=C1OCCN1C(=O)SC2=CC(C(=O)C=3C4=CC=CC=C4C=CC=3)=CC=C21 ASZASBBFPCQNFC-UHFFFAOYSA-N 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
239000012362 glacial acetic acid Substances 0.000 description 2
230000010030 glucose lowering effect Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
230000007774 longterm Effects 0.000 description 2
GPSDUZXPYCFOSQ-UHFFFAOYSA-N m-toluic acid Chemical group CC1=CC=CC(C(O)=O)=C1 GPSDUZXPYCFOSQ-UHFFFAOYSA-N 0.000 description 2
229960003512 nicotinic acid Drugs 0.000 description 2
235000001968 nicotinic acid Nutrition 0.000 description 2
239000011664 nicotinic acid Substances 0.000 description 2
239000012299 nitrogen atmosphere Substances 0.000 description 2
QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
210000000229 preadipocyte Anatomy 0.000 description 2
210000002027 skeletal muscle Anatomy 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
239000011877 solvent mixture Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000003826 tablet Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
150000001467 thiazolidinediones Chemical class 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
NJEMJCTZLIBYSI-UHFFFAOYSA-N (1-oxo-1,3-benzothiazol-6-yl)-phenylmethanone Chemical compound C(C1=CC=CC=C1)(=O)C1=CC2=C(N=CS2=O)C=C1 NJEMJCTZLIBYSI-UHFFFAOYSA-N 0.000 description 1
LLJFNWVJKMVHIL-UHFFFAOYSA-N (2-methoxy-2-oxoethyl)phosphonic acid Chemical compound COC(=O)CP(O)(O)=O LLJFNWVJKMVHIL-UHFFFAOYSA-N 0.000 description 1
125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
125000006621 (C3-C8) cycloalkyl-(C1-C6) alkyl group Chemical group 0.000 description 1
DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
VLXSIHLNPYRFFN-UHFFFAOYSA-N 1,4-dioxane;methanol Chemical compound OC.C1COCCO1 VLXSIHLNPYRFFN-UHFFFAOYSA-N 0.000 description 1
HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical group C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
SBYVQIAOKDDMMS-UHFFFAOYSA-N 1h-pyrrolo[2,3-c]pyridine Chemical group C1=NC=C2NC=CC2=C1.C1=NC=C2NC=CC2=C1 SBYVQIAOKDDMMS-UHFFFAOYSA-N 0.000 description 1
ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 1
TVDCOSKRMWBXNR-UHFFFAOYSA-N 2-[[4-(2-pyrrolo[3,2-c]pyridin-1-ylethoxy)phenyl]methyl]propanedioic acid Chemical compound C1=CC(CC(C(=O)O)C(O)=O)=CC=C1OCCN1C2=CC=NC=C2C=C1 TVDCOSKRMWBXNR-UHFFFAOYSA-N 0.000 description 1
WAQREVHNUDOKLZ-UHFFFAOYSA-N 2-[[4-[3-(2-oxo-1,3-benzothiazol-3-yl)propoxy]phenyl]methyl]propanedioic acid Chemical compound C1=CC(CC(C(=O)O)C(O)=O)=CC=C1OCCCN1C(=O)SC2=CC=CC=C21 WAQREVHNUDOKLZ-UHFFFAOYSA-N 0.000 description 1
125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
125000006012 2-chloroethoxy group Chemical group 0.000 description 1
125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
UOBYKYZJUGYBDK-UHFFFAOYSA-N 2-naphthoic acid Chemical group C1=CC=CC2=CC(C(=O)O)=CC=C21 UOBYKYZJUGYBDK-UHFFFAOYSA-N 0.000 description 1
125000001216 2-naphthoyl group Chemical group C1=C(C=CC2=CC=CC=C12)C(=O)* 0.000 description 1
CZMRCDWAGMRECN-UHFFFAOYSA-N 2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 1
HRTYZCDMCVXIPL-UHFFFAOYSA-N 3-[4-[2-(2-oxo-1,3-benzothiazol-3-yl)ethoxy]phenyl]prop-2-enoic acid Chemical compound C1=CC(C=CC(=O)O)=CC=C1OCCN1C(=O)SC2=CC=CC=C21 HRTYZCDMCVXIPL-UHFFFAOYSA-N 0.000 description 1
RCUSSPASIBGFMF-UHFFFAOYSA-N 3-[4-[2-(2-oxo-1,3-benzoxazol-3-yl)ethoxy]phenyl]prop-2-enoic acid Chemical compound C1=CC(C=CC(=O)O)=CC=C1OCCN1C(=O)OC2=CC=CC=C21 RCUSSPASIBGFMF-UHFFFAOYSA-N 0.000 description 1
HDERQGXUTNIMQJ-UHFFFAOYSA-N 3-[4-[2-(6-benzoyl-2-oxo-1,3-benzothiazol-3-yl)ethoxy]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1OCCN1C(=O)SC2=CC(C(=O)C=3C=CC=CC=3)=CC=C21 HDERQGXUTNIMQJ-UHFFFAOYSA-N 0.000 description 1
XPSYZCWYRWHVCC-UHFFFAOYSA-N 3-o-tert-butyl 1-o-methyl propanedioate Chemical compound COC(=O)CC(=O)OC(C)(C)C XPSYZCWYRWHVCC-UHFFFAOYSA-N 0.000 description 1
HBHHMVNKQWECIS-UHFFFAOYSA-N 4-(2-chloroethoxy)benzaldehyde Chemical compound ClCCOC1=CC=C(C=O)C=C1 HBHHMVNKQWECIS-UHFFFAOYSA-N 0.000 description 1
WWEFFIYYHOTTBZ-UHFFFAOYSA-N 4-(2-pyrrolo[2,3-b]pyridin-1-ylethoxy)benzaldehyde Chemical compound C1=CC(C=O)=CC=C1OCCN1C2=NC=CC=C2C=C1 WWEFFIYYHOTTBZ-UHFFFAOYSA-N 0.000 description 1
JZBBKMPACWSVGJ-UHFFFAOYSA-N 4-(2-pyrrolo[3,2-c]pyridin-1-ylethoxy)benzaldehyde Chemical compound C1=CC(C=O)=CC=C1OCCN1C2=CC=NC=C2C=C1 JZBBKMPACWSVGJ-UHFFFAOYSA-N 0.000 description 1
ZGBUOTIEWXAFPF-UHFFFAOYSA-N 4-[2-(2-oxo-1,3-benzothiazol-3-yl)ethoxy]benzaldehyde Chemical compound C1=CC(C=O)=CC=C1OCCN1C(=O)SC2=CC=CC=C21 ZGBUOTIEWXAFPF-UHFFFAOYSA-N 0.000 description 1
SIDQBYGXZAXYRU-UHFFFAOYSA-N 4-[2-(6-benzoyl-2-oxo-1,3-benzoxazol-3-yl)ethoxy]benzaldehyde Chemical compound C1=CC(C=O)=CC=C1OCCN1C(=O)OC2=CC(C(=O)C=3C=CC=CC=3)=CC=C21 SIDQBYGXZAXYRU-UHFFFAOYSA-N 0.000 description 1
XRHGYUZYPHTUJZ-UHFFFAOYSA-N 4-chlorobenzoic acid Chemical group OC(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-N 0.000 description 1
NNJMFJSKMRYHSR-UHFFFAOYSA-N 4-phenylbenzoic acid Chemical group C1=CC(C(=O)O)=CC=C1C1=CC=CC=C1 NNJMFJSKMRYHSR-UHFFFAOYSA-N 0.000 description 1
KALLIHAAPPNDRW-UHFFFAOYSA-N 6-(2-chlorobenzoyl)-3h-1,3-benzothiazol-2-one Chemical compound ClC1=CC=CC=C1C(=O)C1=CC=C(NC(=O)S2)C2=C1 KALLIHAAPPNDRW-UHFFFAOYSA-N 0.000 description 1
ZMRLJTPDYNPGCD-UHFFFAOYSA-N 6-(2-phenylethenyl)-3h-1,3-benzothiazol-2-one Chemical compound C1=C2SC(=O)NC2=CC=C1C=CC1=CC=CC=C1 ZMRLJTPDYNPGCD-UHFFFAOYSA-N 0.000 description 1
OOFJDPMLCPGLIC-UHFFFAOYSA-N 6-[N-methoxy-C-(4-phenylphenyl)carbonimidoyl]-3H-1,3-benzothiazol-2-one Chemical compound C1(=CC=C(C=C1)C(C1=CC2=C(NC(S2)=O)C=C1)=NOC)C1=CC=CC=C1 OOFJDPMLCPGLIC-UHFFFAOYSA-N 0.000 description 1
FNIQWNQNMXTVJJ-UHFFFAOYSA-N 6-benzoyl-3h-1,3-benzoxazol-2-one Chemical compound C=1C=C2NC(=O)OC2=CC=1C(=O)C1=CC=CC=C1 FNIQWNQNMXTVJJ-UHFFFAOYSA-N 0.000 description 1
QITPMSSAFSZYOP-UHFFFAOYSA-N 6-nitro-3h-1,3-benzothiazol-2-one Chemical compound C1=C([N+]([O-])=O)C=C2SC(O)=NC2=C1 QITPMSSAFSZYOP-UHFFFAOYSA-N 0.000 description 1
244000291564 Allium cepa Species 0.000 description 1
235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
229920001268 Cholestyramine Polymers 0.000 description 1
241000723346 Cinnamomum camphora Species 0.000 description 1
229920002911 Colestipol Polymers 0.000 description 1
102000003706 Complement factor D Human genes 0.000 description 1
108090000059 Complement factor D Proteins 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
208000002249 Diabetes Complications Diseases 0.000 description 1
206010012655 Diabetic complications Diseases 0.000 description 1
GKKZMYDNDDMXSE-UHFFFAOYSA-N Ethyl 3-oxo-3-phenylpropanoate Chemical compound CCOC(=O)CC(=O)C1=CC=CC=C1 GKKZMYDNDDMXSE-UHFFFAOYSA-N 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 1
102000016267 Leptin Human genes 0.000 description 1
108010092277 Leptin Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
GMPKIPWJBDOURN-UHFFFAOYSA-N Methoxyamine Chemical compound CON GMPKIPWJBDOURN-UHFFFAOYSA-N 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
108010016731 PPAR gamma Proteins 0.000 description 1
102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
241000700159 Rattus Species 0.000 description 1
108091006296 SLC2A1 Proteins 0.000 description 1
108091006300 SLC2A4 Proteins 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
102100023536 Solute carrier family 2, facilitated glucose transporter member 1 Human genes 0.000 description 1
102100033939 Solute carrier family 2, facilitated glucose transporter member 4 Human genes 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
210000001789 adipocyte Anatomy 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000003288 aldose reductase inhibitor Substances 0.000 description 1
229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 description 1
125000006307 alkoxy benzyl group Chemical group 0.000 description 1
125000006177 alkyl benzyl group Chemical group 0.000 description 1
VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
125000003705 anilinocarbonyl group Chemical group O=C([*])N([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
239000011324 bead Substances 0.000 description 1
125000005605 benzo group Chemical group 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
238000009835 boiling Methods 0.000 description 1
229960000846 camphor Drugs 0.000 description 1
229930008380 camphor Natural products 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
229960002604 colestipol Drugs 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
235000021004 dietary regimen Nutrition 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
RMDMOWKNRJQQAO-UHFFFAOYSA-N dimethyl 2-[[4-(2-chloroethoxy)phenyl]methyl]propanedioate Chemical compound COC(=O)C(C(=O)OC)CC1=CC=C(OCCCl)C=C1 RMDMOWKNRJQQAO-UHFFFAOYSA-N 0.000 description 1
PJOLRBCVSIGDNA-UHFFFAOYSA-N dimethyl 2-[[4-[2-(6-benzyl-2-oxo-1,3-benzothiazol-3-yl)ethoxy]phenyl]methyl]propanedioate Chemical compound C1=CC(CC(C(=O)OC)C(=O)OC)=CC=C1OCCN1C(=O)SC2=CC(CC=3C=CC=CC=3)=CC=C21 PJOLRBCVSIGDNA-UHFFFAOYSA-N 0.000 description 1
ZPCADPNANBTLSB-UHFFFAOYSA-N dimethyl 2-[[4-[2-[2-oxo-6-(2-phenylethenyl)-1,3-benzothiazol-3-yl]ethoxy]phenyl]methylidene]propanedioate Chemical compound C1=CC(C=C(C(=O)OC)C(=O)OC)=CC=C1OCCN1C(=O)SC2=CC(C=CC=3C=CC=CC=3)=CC=C21 ZPCADPNANBTLSB-UHFFFAOYSA-N 0.000 description 1
UTXMFVSWVJHHNK-UHFFFAOYSA-N dimethyl 2-[[4-[2-[6-(n-methoxy-c-phenylcarbonimidoyl)-2-oxo-1,3-benzothiazol-3-yl]ethoxy]phenyl]methyl]propanedioate Chemical compound C=1C=C2N(CCOC=3C=CC(CC(C(=O)OC)C(=O)OC)=CC=3)C(=O)SC2=CC=1C(=NOC)C1=CC=CC=C1 UTXMFVSWVJHHNK-UHFFFAOYSA-N 0.000 description 1
FELPFTZBWZTNFK-UHFFFAOYSA-N dimethyl 2-[[4-[2-[6-(naphthalen-1-ylmethyl)-2-oxo-1,3-benzothiazol-3-yl]ethoxy]phenyl]methyl]propanedioate Chemical compound C1=CC(CC(C(=O)OC)C(=O)OC)=CC=C1OCCN1C(=O)SC2=CC(CC=3C4=CC=CC=C4C=CC=3)=CC=C21 FELPFTZBWZTNFK-UHFFFAOYSA-N 0.000 description 1
DZHFYJTUUUFAKE-UHFFFAOYSA-N dimethyl 2-[[4-[2-[6-(naphthalen-2-ylmethyl)-2-oxo-1,3-benzothiazol-3-yl]ethoxy]phenyl]methyl]propanedioate Chemical compound C1=CC(CC(C(=O)OC)C(=O)OC)=CC=C1OCCN1C(=O)SC2=CC(CC=3C=C4C=CC=CC4=CC=3)=CC=C21 DZHFYJTUUUFAKE-UHFFFAOYSA-N 0.000 description 1
RDEDEAQBNIFOLB-UHFFFAOYSA-N dimethyl 2-[[4-[2-[6-(naphthalene-1-carbonyl)-2-oxo-1,3-benzothiazol-3-yl]ethoxy]phenyl]methylidene]propanedioate Chemical compound C1=CC(C=C(C(=O)OC)C(=O)OC)=CC=C1OCCN1C(=O)SC2=CC(C(=O)C=3C4=CC=CC=C4C=CC=3)=CC=C21 RDEDEAQBNIFOLB-UHFFFAOYSA-N 0.000 description 1
AUQLSXPEPUHXQI-UHFFFAOYSA-N dimethyl 2-[[4-[2-[6-(naphthalene-2-carbonyl)-2-oxo-1,3-benzothiazol-3-yl]ethoxy]phenyl]methyl]propanedioate Chemical compound C1=CC(CC(C(=O)OC)C(=O)OC)=CC=C1OCCN1C(=O)SC2=CC(C(=O)C=3C=C4C=CC=CC4=CC=3)=CC=C21 AUQLSXPEPUHXQI-UHFFFAOYSA-N 0.000 description 1
MJCLOVFSZXTPFO-UHFFFAOYSA-N dimethyl 2-[[4-[2-[6-[c-(3-chlorophenyl)-n-methoxycarbonimidoyl]-2-oxo-1,3-benzothiazol-3-yl]ethoxy]phenyl]methylidene]propanedioate Chemical compound C=1C=C2N(CCOC=3C=CC(C=C(C(=O)OC)C(=O)OC)=CC=3)C(=O)SC2=CC=1C(=NOC)C1=CC=CC(Cl)=C1 MJCLOVFSZXTPFO-UHFFFAOYSA-N 0.000 description 1
239000008298 dragée Substances 0.000 description 1
230000035622 drinking Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000003480 eluent Substances 0.000 description 1
ZRSDQBKGDNPFLT-UHFFFAOYSA-N ethanol;oxolane Chemical compound CCO.C1CCOC1 ZRSDQBKGDNPFLT-UHFFFAOYSA-N 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
229940125753 fibrate Drugs 0.000 description 1
235000013305 food Nutrition 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
206010061989 glomerulosclerosis Diseases 0.000 description 1
LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
125000006331 halo benzoyl group Chemical group 0.000 description 1
125000006277 halobenzyl group Chemical group 0.000 description 1
125000005059 halophenyl group Chemical group 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
150000002391 heterocyclic compounds Chemical class 0.000 description 1
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
208000006575 hypertriglyceridemia Diseases 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000003914 insulin secretion Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
229940039781 leptin Drugs 0.000 description 1
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
230000037356 lipid metabolism Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000010907 mechanical stirring Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
SURLPDLGPRVTCX-UHFFFAOYSA-N methyl 2-[[4-[2-(6-benzoyl-2-oxo-1,3-benzothiazol-3-yl)ethoxy]phenyl]methyl]-3-(methylamino)-3-oxopropanoate Chemical compound C1=CC(CC(C(=O)NC)C(=O)OC)=CC=C1OCCN1C(=O)SC2=CC(C(=O)C=3C=CC=CC=3)=CC=C21 SURLPDLGPRVTCX-UHFFFAOYSA-N 0.000 description 1
QCLFXHBFWRXYNI-UHFFFAOYSA-N methyl 2-[[4-[2-(6-benzyl-2-oxo-1,3-benzothiazol-3-yl)ethoxy]phenyl]methyl]-3-[2-(methylamino)phenyl]-3-oxopropanoate Chemical compound CNC1=CC=CC=C1C(=O)C(C(=O)OC)CC(C=C1)=CC=C1OCCN1C(=O)SC2=CC(CC=3C=CC=CC=3)=CC=C21 QCLFXHBFWRXYNI-UHFFFAOYSA-N 0.000 description 1
LWTVOSPBXDVVIE-UHFFFAOYSA-N methyl 3-[4-[2-(6-benzoyl-2-oxo-1,3-benzothiazol-3-yl)ethoxy]phenyl]propanoate Chemical compound C1=CC(CCC(=O)OC)=CC=C1OCCN1C(=O)SC2=CC(C(=O)C=3C=CC=CC=3)=CC=C21 LWTVOSPBXDVVIE-UHFFFAOYSA-N 0.000 description 1
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
239000004570 mortar (masonry) Substances 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
230000035772 mutation Effects 0.000 description 1
CPQCSJYYDADLCZ-UHFFFAOYSA-N n-methylhydroxylamine Chemical compound CNO CPQCSJYYDADLCZ-UHFFFAOYSA-N 0.000 description 1
125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
125000000627 niacin group Chemical group 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
238000010606 normalization Methods 0.000 description 1
GMPKIPWJBDOURN-BJUDXGSMSA-N o-methylhydroxylamine Chemical group [11CH3]ON GMPKIPWJBDOURN-BJUDXGSMSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229940127017 oral antidiabetic Drugs 0.000 description 1
208000015124 ovarian disease Diseases 0.000 description 1
LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
125000006684 polyhaloalkyl group Polymers 0.000 description 1
229920000137 polyphosphoric acid Polymers 0.000 description 1
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
229960003912 probucol Drugs 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
150000003222 pyridines Chemical class 0.000 description 1
125000005400 pyridylcarbonyl group Chemical group N1=C(C=CC=C1)C(=O)* 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000002207 retinal effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
RVZHUQPIBHMAEX-UHFFFAOYSA-N sodium;isocyanate Chemical compound [Na+].[N-]=C=O RVZHUQPIBHMAEX-UHFFFAOYSA-N 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000006190 sub-lingual tablet Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
238000001665 trituration Methods 0.000 description 1
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
229960001641 troglitazone Drugs 0.000 description 1
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
201000002282 venous insufficiency Diseases 0.000 description 1
229940100445 wheat starch Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Hematology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Vascular Medicine (AREA)
Neurosurgery (AREA)
Hospice & Palliative Care (AREA)
Reproductive Health (AREA)
Nutrition Science (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

SK1116-2002A 2000-02-02 2001-02-01 Kondenzované azolové zlúčeniny a ich použitie ako hypoglykemické prostriedky SK11162002A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0001289A FR2804431A1 (fr)	2000-02-02	2000-02-02	Nouveaux derives heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/FR2001/000304 WO2001057002A1 (fr)	2000-02-02	2001-02-01	Derives d'azoles condenses et leur utilisation comme agents hypoglycemiants

Publications (1)

Publication Number	Publication Date
SK11162002A3 true SK11162002A3 (sk)	2003-01-09

Family

ID=8846564

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1116-2002A SK11162002A3 (sk)	2000-02-02	2001-02-01	Kondenzované azolové zlúčeniny a ich použitie ako hypoglykemické prostriedky

Country Status (25)

Country	Link
US (1)	US6919362B2 (es)
EP (1)	EP1252150B1 (es)
JP (1)	JP2003521541A (es)
KR (1)	KR100495365B1 (es)
CN (1)	CN1211374C (es)
AR (1)	AR030048A1 (es)
AT (1)	ATE242223T1 (es)
AU (1)	AU775281B2 (es)
BR (1)	BR0108046A (es)
CA (1)	CA2398674A1 (es)
CZ (1)	CZ20022646A3 (es)
DE (1)	DE60100335T2 (es)
DK (1)	DK1252150T3 (es)
EA (1)	EA004676B1 (es)
ES (1)	ES2201029T3 (es)
FR (1)	FR2804431A1 (es)
HU (1)	HUP0204354A3 (es)
MX (1)	MXPA02007402A (es)
NO (1)	NO20023662L (es)
NZ (1)	NZ520260A (es)
PL (1)	PL356911A1 (es)
PT (1)	PT1252150E (es)
SK (1)	SK11162002A3 (es)
WO (1)	WO2001057002A1 (es)
ZA (1)	ZA200205599B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2845601B1 (fr) *	2002-10-11	2005-07-08	Servier Lab	Nouvelle association entre un compose heterocyclique et un agent antioxydant et les compositions pharmaceutiques qui les contiennent
FR2845998A1 (fr) *	2002-10-18	2004-04-23	Servier Lab	Nouveaux composes benzoxazoles ou oxazolopyridines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7129264B2 (en) *	2003-04-16	2006-10-31	Bristol-Myers Squibb Company	Biarylmethyl indolines and indoles as antithromboembolic agents
JP2006526660A (ja) *	2003-06-05	2006-11-24	バーテックス　ファーマシューティカルズ　インコーポレイテッド	Ｖｒ１レセプターのモジュレーター
FR2858321B1 (fr) *	2003-07-28	2006-01-20	Servier Lab	Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2868313B1 (fr) *	2004-03-31	2008-08-15	Servier Lab	Nouvelle association entre un compose heterocyclique et un agent antioxydant et les compositions pharmaceutiques qui les contiennent
FR2881137B1 (fr) *	2005-01-27	2007-03-02	Servier Lab	Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE102005026762A1 (de) *	2005-06-09	2006-12-21	Sanofi-Aventis Deutschland Gmbh	Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
DE102005026808A1 (de)	2005-06-09	2006-12-14	Sanofi-Aventis Deutschland Gmbh	Benzooxazol-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
FR2894965B1 (fr) *	2005-12-20	2008-01-25	Servier Lab	Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2898125B1 (fr) *	2006-03-06	2008-06-13	Servier Lab	Nouveaux derives heterocycliques cycloalkyles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2903404B1 (fr) *	2006-07-10	2008-08-22	Servier Lab	Nouveaux derives tetracycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2078016B1 (en)	2006-10-19	2012-02-01	Signal Pharmaceuticals LLC	Heteroaryl compounds, compositions thereof, and methods of treatment therewith
US20100158829A1 (en) *	2008-12-24	2010-06-24	Conopco, Inc., D/B/A Unilever	Method and Composition for Color Modulation
DE102009012314A1 (de)	2009-03-09	2010-09-16	Bayer Schering Pharma Aktiengesellschaft	Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung
AU2014237340C1 (en)	2013-03-15	2018-11-08	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
EA202092627A1 (ru)	2013-11-18	2021-09-30	Глобал Блад Терапьютикс, Инк.	Соединения и их применения для модуляции гемоглобина

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4116090A1 (de) *	1991-05-17	1992-11-19	Basf Ag	(alpha)-phenylacrylsaeurederivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung von schaedlingen und schadpilzen
DE19546918A1 (de) *	1995-12-15	1997-06-19	Bayer Ag	Bicyclische Heterocyclen

2000
- 2000-02-02 FR FR0001289A patent/FR2804431A1/fr active Pending
2001
- 2001-02-01 EA EA200200810A patent/EA004676B1/ru not_active IP Right Cessation
- 2001-02-01 PL PL01356911A patent/PL356911A1/xx not_active Application Discontinuation
- 2001-02-01 SK SK1116-2002A patent/SK11162002A3/sk unknown
- 2001-02-01 CZ CZ20022646A patent/CZ20022646A3/cs unknown
- 2001-02-01 AU AU31953/01A patent/AU775281B2/en not_active Ceased
- 2001-02-01 US US10/203,113 patent/US6919362B2/en not_active Expired - Fee Related
- 2001-02-01 DK DK01904021T patent/DK1252150T3/da active
- 2001-02-01 WO PCT/FR2001/000304 patent/WO2001057002A1/fr not_active Ceased
- 2001-02-01 BR BR0108046-6A patent/BR0108046A/pt not_active IP Right Cessation
- 2001-02-01 EP EP01904021A patent/EP1252150B1/fr not_active Expired - Lifetime
- 2001-02-01 AT AT01904021T patent/ATE242223T1/de not_active IP Right Cessation
- 2001-02-01 ES ES01904021T patent/ES2201029T3/es not_active Expired - Lifetime
- 2001-02-01 NZ NZ520260A patent/NZ520260A/en unknown
- 2001-02-01 CN CNB018043399A patent/CN1211374C/zh not_active Expired - Fee Related
- 2001-02-01 MX MXPA02007402A patent/MXPA02007402A/es active IP Right Grant
- 2001-02-01 CA CA002398674A patent/CA2398674A1/fr not_active Abandoned
- 2001-02-01 KR KR10-2002-7009942A patent/KR100495365B1/ko not_active Expired - Fee Related
- 2001-02-01 DE DE60100335T patent/DE60100335T2/de not_active Expired - Fee Related
- 2001-02-01 HU HU0204354A patent/HUP0204354A3/hu unknown
- 2001-02-01 JP JP2001556852A patent/JP2003521541A/ja active Pending
- 2001-02-01 PT PT01904021T patent/PT1252150E/pt unknown
- 2001-02-02 AR ARP010100496A patent/AR030048A1/es unknown
2002
- 2002-07-12 ZA ZA200205599A patent/ZA200205599B/en unknown
- 2002-08-01 NO NO20023662A patent/NO20023662L/no unknown

Also Published As

Publication number	Publication date
ATE242223T1 (de)	2003-06-15
NO20023662L (no)	2002-09-27
AU775281B2 (en)	2004-07-29
KR20020072301A (ko)	2002-09-14
AR030048A1 (es)	2003-08-13
PL356911A1 (en)	2004-07-12
US20030040533A1 (en)	2003-02-27
HUP0204354A2 (hu)	2003-04-28
US6919362B2 (en)	2005-07-19
FR2804431A1 (fr)	2001-08-03
KR100495365B1 (ko)	2005-06-14
AU3195301A (en)	2001-08-14
JP2003521541A (ja)	2003-07-15
HUP0204354A3 (en)	2006-01-30
NO20023662D0 (no)	2002-08-01
CN1396915A (zh)	2003-02-12
WO2001057002A1 (fr)	2001-08-09
DE60100335D1 (de)	2003-07-10
DE60100335T2 (de)	2004-05-06
ZA200205599B (en)	2003-12-01
CA2398674A1 (fr)	2001-08-09
MXPA02007402A (es)	2002-12-09
DK1252150T3 (da)	2003-09-29
EP1252150A1 (fr)	2002-10-30
CN1211374C (zh)	2005-07-20
PT1252150E (pt)	2003-09-30
NZ520260A (en)	2004-05-28
HK1052007A1 (en)	2003-08-29
EA004676B1 (ru)	2004-06-24
EA200200810A1 (ru)	2003-02-27
ES2201029T3 (es)	2004-03-16
CZ20022646A3 (cs)	2002-11-13
EP1252150B1 (fr)	2003-06-04
BR0108046A (pt)	2003-01-28

Publication	Publication Date	Title
SK11162002A3 (sk)	2003-01-09	Kondenzované azolové zlúčeniny a ich použitie ako hypoglykemické prostriedky
EP2077846A2 (en)	2009-07-15	Benzoxazepine compounds, their preparation and use
WO2008006969A2 (fr)	2008-01-17	Nouveaux derives tetracycuques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7071221B2 (en)	2006-07-04	Heterocyclic oxime compounds
US20080113974A1 (en)	2008-05-15	Heterocyclic Oxime Compounds, A Process For Their Preparation And Pharmaceutical Compositions Containing Them.
US7456293B2 (en)	2008-11-25	Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use
WO2003027108A1 (fr)	2003-04-03	Derives heterocycliques et leur utilisation en tant qu'agents hypoglycemiants et hypolipemiants
US20090239917A1 (en)	2009-09-24	Heterocyclic Cycloalkyl Compounds, a Process for their Preparation and Pharmaceutical Compositions Containing Them
US20090274674A1 (en)	2009-11-05	Heterocyclic Oxime Compounds, Process for Their Preparation and Pharmaceutical Compositions Containing Them
HK1115127A (en)	2008-11-21	Novel heterocyclic oxime derivatives, method for preparing same and use thereof as hypoglycaemic or hypolipidemic agents
HK1071748B (en)	2009-10-30	New heterocyclic oxime compounds, a process for their preparation and pharmaceutical compositions containing them